The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
Open Access
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 29 (10), 5701-5709
- https://doi.org/10.1007/s00520-021-06048-5
Abstract
Purpose To discuss the role of benzydamine in the prevention and treatment of radiation-induced oral mucositis (OM) in head and neck (H&N) cancer patients. This document represents an expert opinion paper on indications and key-role aspects in OM pathogenesis, prevention and treatment. Oral mucositis OM represents a common side effect of chemotherapy (CHT) and radiotherapy (RT). It consists in a painful erythema involving the oral cavity mucosa, which may progress to ulceration. Five biologically dynamic phases are considered crucial in mucositis: “initiation, signalling, amplification, ulceration and healing”. Oral environment and microbiota are fundamental in mucositis development being involved in susceptibility to infections and in ulceration consequences. Different agents against mucositis have been studied and the use of benzydamine is strongly supported in literature. The Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO) guidelines recommend its use for the prevention of OM in H&N patients undergoing RT and RT/CHT. Benzydamine Benzydamine is a local anti-inflammatory drug with analgesic properties. It can decrease TNF-α, IL-1β and prostaglandin synthesis, also inhibiting leukocyte-endothelial interactions, neutrophil degranulation, vasodilation and vascular permeability. Literature agrees on the beneficial effects of benzydamine in preventing and reducing oral mucositis severity in H&N cancer patients undergoing RT/CHT. Conclusions Mucositis represents a major concern in H&N cancer patients and a clinical and economical issue. A multimodal and multidisciplinary approach is needed for its management. International guidelines recommend benzydamine for OM prevention and treatment in H&N cancer patients, but further “real world” trials should be designed.Keywords
Funding Information
- Angelini Pharma
This publication has 45 references indexed in Scilit:
- Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinasesSupportive Care in Cancer, 2013
- Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing RatsPLOS ONE, 2012
- Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipientsSupportive Care in Cancer, 2012
- Oral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without ChemotherapyThe Open Cancer Journal, 2011
- Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: A drug trailContemporary Clinical Dentistry, 2011
- A systematic review of oral fungal infections in patients receiving cancer therapySupportive Care in Cancer, 2010
- Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trialEuropean Journal of Cancer Care, 2009
- Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositisSupportive Care in Cancer, 2006
- Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapySupportive Care in Cancer, 2005
- INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION AND PROTECTION AGAINST ENDOTOXIN TOXICITY BY BENZIDAMINECytokine, 1996